Tags

Type your tag names separated by a space and hit enter

Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
Circ Heart Fail 2012; 5(5):586-93CH

Abstract

BACKGROUND

Patients with heart failure (HF) and atrial fibrillation (AF) may differ from the larger HF population with respect to comorbidities, including renal impairment and overall prognosis. Associated cardiorenal interactions may mitigate the effects of pharmacological agents. Our primary objective was to assess the impact of mineralocorticoid receptor antagonists on cardiovascular mortality in patients with AF and HF enrolled in the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial.

METHODS AND RESULTS

All 1376 patients randomized in the AF-CHF trial were included. The median baseline creatinine was 105.2 (Q1 88.4, Q3 125.0) μmol/L, and the median estimated glomerular filtration rate was 62.3 (Q1 49.0, Q3 77.2) mL/min per 1.73 m(2). The renal function was moderately or severely impaired (ie, estimated glomerular filtration rate <60 mL/min per 1.73 m(2)) in 46.5% of patients. In multivariable analyses, increased creatinine was associated with worsening HF but not mortality. Mineralocorticoid receptor antagonists were prescribed in 44.8% and were independently associated with a 1.4-fold increase in total mortality (hazard ratio, 1.4; 95% CI [1.1-1.8]; P=0.005) and a 1.4-fold increase in cardiovascular mortality (hazard ratio, 1.4; 95% CI [1.1-1.9]; P=0.009). This was driven by an increased incidence of sudden cardiac death (hazard ratio, 2.0; 95% CI [1.3, 3.0]; P=0.001).

CONCLUSIONS

Renal dysfunction was highly prevalent in patients with AF and HF. Mineralocorticoid receptor antagonists were independently associated with an increased incidence of cardiovascular deaths, predominantly of presumed arrhythmic cause. Although these provocative findings merit prospective validation, they underscore the importance of careful monitoring of renal function and electrolytes in patients with AF and HF receiving mineralocorticoid receptor antagonists.

Authors+Show Affiliations

Montreal Heart Institute, Montreal Heart Institute Coordinating Center, and Université de Montréal, Montreal, QC, Canada. eileen.omeara@umontreal.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22798522

Citation

O'Meara, Eileen, et al. "Mineralocorticoid Receptor Antagonists and Cardiovascular Mortality in Patients With Atrial Fibrillation and Left Ventricular Dysfunction: Insights From the Atrial Fibrillation and Congestive Heart Failure Trial." Circulation. Heart Failure, vol. 5, no. 5, 2012, pp. 586-93.
O'Meara E, Khairy P, Blanchet MC, et al. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. Circ Heart Fail. 2012;5(5):586-93.
O'Meara, E., Khairy, P., Blanchet, M. C., de Denus, S., Pedersen, O. D., Levesque, S., ... Roy, D. (2012). Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. Circulation. Heart Failure, 5(5), pp. 586-93.
O'Meara E, et al. Mineralocorticoid Receptor Antagonists and Cardiovascular Mortality in Patients With Atrial Fibrillation and Left Ventricular Dysfunction: Insights From the Atrial Fibrillation and Congestive Heart Failure Trial. Circ Heart Fail. 2012 Sep 1;5(5):586-93. PubMed PMID: 22798522.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. AU - O'Meara,Eileen, AU - Khairy,Paul, AU - Blanchet,Malorie Chabot, AU - de Denus,Simon, AU - Pedersen,Ole D, AU - Levesque,Sylvie, AU - Talajic,Mario, AU - Ducharme,Anique, AU - White,Michel, AU - Racine,Normand, AU - Rouleau,Jean-Lucien, AU - Tardif,Jean-Claude, AU - Roy,Denis, AU - ,, Y1 - 2012/07/12/ PY - 2012/7/17/entrez PY - 2012/7/17/pubmed PY - 2012/12/10/medline SP - 586 EP - 93 JF - Circulation. Heart failure JO - Circ Heart Fail VL - 5 IS - 5 N2 - BACKGROUND: Patients with heart failure (HF) and atrial fibrillation (AF) may differ from the larger HF population with respect to comorbidities, including renal impairment and overall prognosis. Associated cardiorenal interactions may mitigate the effects of pharmacological agents. Our primary objective was to assess the impact of mineralocorticoid receptor antagonists on cardiovascular mortality in patients with AF and HF enrolled in the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. METHODS AND RESULTS: All 1376 patients randomized in the AF-CHF trial were included. The median baseline creatinine was 105.2 (Q1 88.4, Q3 125.0) μmol/L, and the median estimated glomerular filtration rate was 62.3 (Q1 49.0, Q3 77.2) mL/min per 1.73 m(2). The renal function was moderately or severely impaired (ie, estimated glomerular filtration rate <60 mL/min per 1.73 m(2)) in 46.5% of patients. In multivariable analyses, increased creatinine was associated with worsening HF but not mortality. Mineralocorticoid receptor antagonists were prescribed in 44.8% and were independently associated with a 1.4-fold increase in total mortality (hazard ratio, 1.4; 95% CI [1.1-1.8]; P=0.005) and a 1.4-fold increase in cardiovascular mortality (hazard ratio, 1.4; 95% CI [1.1-1.9]; P=0.009). This was driven by an increased incidence of sudden cardiac death (hazard ratio, 2.0; 95% CI [1.3, 3.0]; P=0.001). CONCLUSIONS: Renal dysfunction was highly prevalent in patients with AF and HF. Mineralocorticoid receptor antagonists were independently associated with an increased incidence of cardiovascular deaths, predominantly of presumed arrhythmic cause. Although these provocative findings merit prospective validation, they underscore the importance of careful monitoring of renal function and electrolytes in patients with AF and HF receiving mineralocorticoid receptor antagonists. SN - 1941-3297 UR - https://www.unboundmedicine.com/medline/citation/22798522/Mineralocorticoid_receptor_antagonists_and_cardiovascular_mortality_in_patients_with_atrial_fibrillation_and_left_ventricular_dysfunction:_insights_from_the_Atrial_Fibrillation_and_Congestive_Heart_Failure_Trial_ L2 - http://www.ahajournals.org/doi/full/10.1161/CIRCHEARTFAILURE.111.965160?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -